Oct 7 (Reuters) - AstraZeneca (AZN.L), opens new tab said on Monday it would pay up to $1.92 billion to CSPC Pharmaceutical Group Ltd (1093.HK), opens new tab in an exclusive licence agreement to ...

In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Sell rating on AstraZeneca (AZN – Research Report), with a price target of £105.00. The company’s shares opened ...

After more than three billion doses, the Oxford-AstraZeneca Covid vaccine is being withdrawn. AstraZeneca said it was "incredibly proud" of the vaccine, but it had made a commercial decision.

Steven Goldstein is based in London and responsible for MarketWatch's coverage of financial markets in Europe, with a particular focus on global macro and commodities. Previously, he was ...

This AstraZeneca 2021 business report presents the course of business throughout the respective business year. The report complies with the disclosure requirement for corporate entities and ...

Immunai Inc., a New York-based artificial intelligence and biotech company specializing in mapping the human immune system, ...

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is ...

In a report released today, Emily Field from Barclays maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price target of £140.00. The company’s shares closed yesterday at ...

Astrazeneca has entered into a licensing agreement, potentially worth up to $2bn (£1.5bn), with China's CPSC Pharmaceutical ...

AstraZeneca is the main vaccine offered in Australia but people increasingly don't want it Australian doctors have reported a surge in the number of people cancelling their vaccine appointments ...

The year 2021 was one of big impact for pharmaceutical leader AstraZeneca, which supplied over 2.5 billion doses of COVID-19 vaccines to more than 180 countries. But when it comes to ESG reporting ...